Mind Medicine Inc Ordinary Shares MNMD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
MindMed Announces New Employee Inducement Grants
-
MindMed to Participate in September Investor Conferences
-
MindMed readying Phase III trials for LSD therapy to treat anxiety
-
MindMed Reports Second Quarter 2024 Financial Results and Business Updates
-
Psychedelic drug contender stocks drop after FDA rejects MDMA treatment
-
Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering
-
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
-
MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference
Trading Information
- Previous Close Price
- $5.63
- Day Range
- $5.51–5.63
- 52-Week Range
- $2.41–12.22
- Bid/Ask
- $5.55 / $5.63
- Market Cap
- $451.94 Mil
- Volume/Avg
- 270,689 / 911,927
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 57
- Website
- https://www.mindmed.co
Comparables
Valuation
|
Metric
|
MNMD
|
RARE
|
TERN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.01 | 12.04 | 2.61 |
Price/Sales | — | 9.50 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MNMD
|
RARE
|
TERN
|
|---|---|---|---|
Quick Ratio | 5.81 | 3.19 | 20.57 |
Current Ratio | 5.92 | 3.54 | 21.02 |
Interest Coverage | — | −8.24 | — |
Quick Ratio
MNMD
RARE
TERN
Profitability
|
Metric
|
MNMD
|
RARE
|
TERN
|
|---|---|---|---|
Return on Assets (Normalized) | −35.50% | −31.64% | −28.87% |
Return on Equity (Normalized) | −49.83% | −218.50% | −30.36% |
Return on Invested Capital (Normalized) | −49.35% | −168.31% | −34.37% |
Return on Assets
MNMD
RARE
TERN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Rjvzkjfjt | Wndb | $530.7 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Hxmjwyxz | Mbsdccf | $121.2 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Qllbnfv | Dwsqzb | $115.5 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zhrqhcr | Tmmtqjb | $35.4 Bil | |||
| argenx SE ADR
ARGX
| Vppcmzqx | Lhmnl | $32.8 Bil | |||
| BioNTech SE ADR
BNTX
| Lgpnqdxvs | Ryyg | $28.5 Bil | |||
| Moderna Inc
MRNA
| Kwwdjdmc | Nxfc | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Krnxlnqdd | Lmkyj | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Rkgldlft | Hsytzly | $13.3 Bil | |||
| Incyte Corp
INCY
| Jcqhgzc | Vyxntlm | $13.1 Bil |
United States